Baird raised the firm’s price target on Castle Biosciences (CSTL) to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results and raised revenue outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL: